**Core Concept**
Baricitinib is a selective inhibitor of Janus kinase 1 (JAK1), which plays a crucial role in the signaling pathways of various cytokines, including those involved in inflammation. By inhibiting JAK1, baricitinib reduces the production of pro-inflammatory cytokines, leading to its use in the treatment of rheumatoid arthritis.

**Why the Correct Answer is Right**
The correct answer will be the statement that is not supported by the pharmacological properties or clinical use of baricitinib. Baricitinib has been shown to be effective in reducing symptoms of rheumatoid arthritis, improving physical function, and slowing disease progression. It also has a favorable safety profile, with common side effects including headache, nausea, and diarrhea.

**Why Each Wrong Option is Incorrect**
**Option A:** Baricitinib is indeed a selective inhibitor of JAK1, which is a key component of the cytokine signaling pathway. This makes Option A a true statement.
**Option B:** While baricitinib is not a biologic agent, it is often used in combination with biologics to enhance treatment outcomes. This makes Option B a true statement.
**Option C:** Unfortunately, this statement is incorrect. Baricitinib is not a corticosteroid, but rather a small molecule inhibitor of JAK1.

**Clinical Pearl / High-Yield Fact**
When considering the use of baricitinib or other JAK inhibitors, it's essential to monitor patients for signs of infection, as these medications can increase the risk of serious infections, including herpes zoster.

**Correct Answer: C. Baricitinib is not a corticosteroid.**